The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IACH Focus on Leukemia 2020 | The 2020 highlights in MDS
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the drugs in development for myelodysplastic syndromes (MDS). For lower-risk MDS, Prof. Cluzeau highlights the Phase III trial of luspatercep in patients with lower-risk MDS with ring sideroblasts as well as the Phase II trial results of imetelstat, a telomerase inhibitor, that shows good transfusion independence. Prof. Cluzeau also discusses the Phase I results of roxadustat, an oral HIF prolyl-hydroxylase inhibitor currently being evaluated in lower-risk MDS with anemia. For the treatment of higher-risk MDS, Prof. Cluzeau outlines novel agents under investigation, including APR-246 in combination with azacitidine as well as magrolimab, a CD47 inhibitor and pevonedistat, a selective NEDD8 inhibitor. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
Disclosures
Clinical Research: Aprea (PI GFM APR), Novartis, Alexion, Celgene/BMS, Amgen, Syros, Kartos, Arog
Advisory boards: Celgene, Abbvie, Jazz Pharma, Roche, Novartis, Agios
Education: Novartis, Amgen, Sanofi, Astellas
International congresses: Sanofi, Pfizer, Celgene, Novartis
